Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
We previously reported that cynomolgus monkeys vaccinated with the human immunodeficiency virus (HIV)-1 Tat protein controlled infection after challenge with the simian human immunodeficiency virus (SHIV) 89.6P(cy243) for up to 2 y of follow-up. To evaluate the breadth of the protective immunity elicited by the Tat protein, the vaccines along with the naïve monkeys were intravenously rechallenged with a fivefold higher dose (50 MID(50)) of the same SHIV-89.6P(cy243). The vaccinated monkeys exhibited a statistically significant and long-lasting reduction of viral replication compared to control monkeys. This effect was associated with a strong anamnestic response to Tat, while responses to Gag and Env were nearly undetectable. Taken together, these data provide further evidence for the usefulness of Tat-based vaccines.
Borsetti
Alessandra
A
National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Baroncelli
Silvia
S
Maggiorella
Maria Teresa
MT
Moretti
Sonia
S
Fanales-Belasio
Emanuele
E
Sernicola
Leonardo
L
Tripiciano
Antonella
A
Macchia
Iole
I
Michelini
Zuleika
Z
Belli
Roberto
R
Farcomeni
Stefania
S
Pavone-Cossut
Maria Rosaria
MR
Negri
Donatella
D
Caputo
Antonella
A
Bellino
Stefania
S
Butto
Stefano
S
Titti
Fausto
F
Cafaro
Aurelio
A
Ensoli
Barbara
B